Greg Kunst is an award-winning biotech and life sciences chief executive officer, board chairman, board director, investor, and strategic advisor. Kunst currently serves as Chief Executive Officer and board member at Valitor, as a board director at FELIQS, and as chairman of the board at BioMimetix, with an additional board director role at Pr3vent INC. Previously, Kunst founded Aurion Biotech and served as its Chief Executive Officer and board director from 2021 to 2025. Earlier experience includes Senior Director, Global Market Access and Business Development at Glaukos (2015–2018) and roles at Alcon, including Global Marketing Director - Retina Pharmaceuticals (2013–2015) and Global Product Director - Surgical Glaucoma. Education includes an MBA from Vanderbilt University (2004–2006) and completion of executive programs at The Tuck School of Business at Dartmouth (Novartis ADVANCE, 2014) and Novartis (Leadership, 2013), along with a B.S. in Economics from Brigham Young University (1997–2002).
This person is not in the org chart
This person is not in any teams
This person is not in any offices